Cellectis Operating Income Over Time
| CLLS Stock | USD 3.90 0.09 2.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cellectis Performance and Cellectis Correlation. Cellectis | Build AI portfolio with Cellectis Stock |
Is there potential for Biotechnology market expansion? Will Cellectis introduce new products? Factors like these will boost the valuation of Cellectis. Projected growth potential of Cellectis fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Cellectis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Revenue Per Share | Quarterly Revenue Growth 1.059 | Return On Assets | Return On Equity |
The market value of Cellectis SA is measured differently than its book value, which is the value of Cellectis that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectis' value that differs from its market value or its book value, called intrinsic value, which is Cellectis' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Cellectis' market value can be influenced by many factors that don't directly affect Cellectis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cellectis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cellectis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cellectis' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Cellectis SA and related stocks such as Alto Neuroscience, AC Immune, and Aldeyra Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANRO | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (29.2 M) | (37.8 M) | (68.6 M) | (68.6 M) | (61.7 M) | (58.7 M) |
| ACIU | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | 10.7 M | 18.6 M | (10.5 M) | (22.5 M) | (49.5 M) | 44.5 M | (61.3 M) | (79 M) | (70.8 M) | (53.6 M) | (52.4 M) | (47.1 M) | (44.8 M) |
| ALDX | (2.1 M) | (2.1 M) | (1.1 M) | (3.7 M) | (7.3 M) | (12 M) | (18.7 M) | (22.5 M) | (39.7 M) | (63.1 M) | (34.7 M) | (56.2 M) | (62.7 M) | (42.8 M) | (60.1 M) | (54.1 M) | (51.4 M) |
| AMRN | 1.1 M | (44.4 M) | (116.8 M) | (182.1 M) | (96 M) | (98.2 M) | (65.6 M) | (45.6 M) | (108.2 M) | (24.3 M) | (19.7 M) | 10.5 M | (105.9 M) | (67.6 M) | (91.8 M) | (82.6 M) | (78.5 M) |
| DRTS | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (9.2 M) | (13.8 M) | (32.1 M) | 35.7 M | (36 M) | (32.4 M) | (30.8 M) |
| LRMR | (13.2 M) | (13.2 M) | (13.8 M) | (13.8 M) | (35.5 M) | (73.8 M) | (57.1 M) | (53.9 M) | (62.7 M) | (23.2 M) | (42.8 M) | (50.5 M) | (36.5 M) | (41.8 M) | (90.9 M) | (81.8 M) | (77.7 M) |
| SLN | (933 K) | (5.8 M) | (26.3 M) | (9.1 M) | (12.1 M) | (9.8 M) | (11.9 M) | (14.4 M) | (20.6 M) | (22.7 M) | (35.8 M) | (45.8 M) | (61 M) | (49.6 M) | (63.3 M) | (57 M) | (54.1 M) |
| DBVT | (7.5 M) | (9.4 M) | (17.7 M) | (27.5 M) | (29.8 M) | (54.3 M) | (122.1 M) | (173.9 M) | (190.1 M) | (171 M) | (158.8 M) | (98.6 M) | (96.6 M) | (76.4 M) | (120.5 M) | (108.5 M) | (113.9 M) |
| MREO | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (36.2 M) | (45.3 M) | (35.2 M) | (50.4 M) | (48.2 M) | (28.3 M) | (53.7 M) | (28.4 M) | (47.4 M) | (42.6 M) | (44.8 M) |
| KRRO | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (18.9 M) | (20.7 M) | (27.6 M) | (84 M) | (59 M) | (84.5 M) | (91.9 M) | (82.7 M) | (78.6 M) |
Cellectis SA and related stocks such as Alto Neuroscience, AC Immune, and Aldeyra Operating Income description
Operating Income is the amount of profit realized from Cellectis SA operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cellectis SA is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Cellectis SA | CLLS |
| Classification | Cancer Fighters |
| Business Address | 8, rue de |
| Exchange | NASDAQ Exchange |
USD 3.9
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.